Lucid Diagnostics

Update in progress

LUCD (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Lucid Diagnostics Inc. is a commercial‑stage medical diagnostics company in the United States focused on patients with gastroesophageal reflux disease at risk of esophageal precancer and cancer, particularly esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test, uses samples collected with the EsoCheck device to enable early detection and prevent deaths. Founded in 2018 and based in New York, it is a subsidiary of PAVmed Inc.

Company score

Sentiment: 0.45; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.40; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.29; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.18; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive